MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from term loan,
net of issuance...
$47,946K
Proceeds from issuance of
common stock in...
$14,331K
Proceeds from sale of
common stock through...
$5,038K
Proceeds from option
exercises
$516K
Net cash provided by
financing activities
$56,098K
Canceled cashflow
$11,733K
Net increase in
cash, cash...
$17,227K
Canceled cashflow
$38,871K
Principal payments on term
loan payable to a bank
-$11,733K
Non-cash stock
compensation expense
$3,817K
Accrued expenses
$2,254K
Depreciation expense
$845K
Accounts payable
$802K
Accretion of debt discount
$360K
Non-cash lease expense
$321K
Loss on the sale and
disposal of fixed assets
-$306K
Deferred income
$178K
Non-cash interest
expense
$138K
Impairment of fixed assets
$90K
Proceeds from the sale of
fixed assets
$27K
Net cash used in
operating activities
-$38,311K
Net cash used in
investing activities
-$560K
Canceled cashflow
$9,111K
Canceled cashflow
$27K
Net loss
-$38,182K
Change in fair value of
warrant liabilities
-$8,199K
Purchase of fixed assets
$587K
Lease liability
-$509K
Prepaid expenses and
other current assets
$508K
Other assets
$24K
Back
Back
Cash Flow
source: myfinsight.com
Candel Therapeutics, Inc. (CADL)
Candel Therapeutics, Inc. (CADL)